Profusa Inc. surges as investors cheer its latest breakthrough news, with stocks have been trading up by 110.82 percent.
Click Here for a Millionaire's POV on Trading PFSA
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- Shares of PFSA dropped 18% after the company announced a non-binding term sheet to buy a privately held diagnostics and toxicology testing business.
- The term sheet is preliminary, so PFSA and the target can still walk away if final terms are not reached.
- The target is already commercial-stage, hinting that Profusa Inc. wants a faster path to revenue than its current pipeline.
- Traders are questioning whether PFSA’s weak balance sheet can handle an acquisition without serious dilution or new debt.
Live Update At 07:47:11 EDT: On Tuesday, August 18, 2026 Profusa Inc. stock [NASDAQ: PFSA] is trending up by 110.82%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
PFSA has been trading like a classic low-float battleground name. On the daily chart, Profusa Inc. ran from under $1 in late July to as high as $6.77 by 2026/08/17 before closing at $4.53. That’s a massive percentage move in a few weeks, and it screams volatility. For active traders, PFSA is a pure momentum vehicle, not a steady compounder.
The intraday tape shows wild swings as well, with PFSA trading between roughly $8.29 and $12.77 in the latest session. That kind of $4 range in a single day tells you funds are not setting it and forgetting it — they are day-trading the headlines.
More Breaking News
- DFSC Stock Jumps As Traders Pile Into High-Volatility Move
- COHR Stock Jumps As Analysts Chase AI Datacenter Boom
- Nebius Group NBIS Stock Soars On Explosive AI Cloud Growth
- SOUN Stock Slips As Halper Sadeh Probes Governance
Financially, Profusa Inc. is still deep in the red. Q1 2026 showed a net loss of about $3.46M and negative operating cash flow of roughly $2.6M. PFSA ended the quarter with only $375,000 in cash and negative equity of about $28.2M. The company carries around $29.1M in total liabilities and has a current ratio effectively at zero, signaling serious balance-sheet stress. For traders, that means any new deal, like this diagnostics acquisition, raises urgent questions about funding, dilution, and going-concern risk.
Why Traders Are Watching PFSA After The Drop
Profusa Inc. is in the spotlight because the market just delivered a harsh verdict on its latest strategic move. PFSA shares fell 18% after the company signed a non-binding term sheet to buy a privately held commercial-stage diagnostics and toxicology testing company. When a stock already known for violent swings drops that hard on news, traders pay attention.
On paper, the idea makes sense. PFSA has struggled with losses and has limited cash. Buying a business that already generates diagnostics and toxicology revenue sounds like a shortcut to a more mature commercial profile. For some companies, that kind of acquisition jump-starts growth and stabilizes the story.
But the term sheet is non-binding, and that matters. It signals PFSA and the target are still feeling each other out. Key details — price, structure, financing — may not be set in stone. Traders see uncertainty, not clarity. With Profusa Inc. carrying negative equity and a pile of liabilities, the obvious question for PFSA is: how will this deal be paid for?
If PFSA funds it with stock, traders expect dilution. If PFSA loads up more debt, the already stressed balance sheet gets even riskier. That’s likely why the stock sold off. In fast-moving names like PFSA, the first reaction often comes from fear, not patience. Short sellers lean in, and momentum traders bail until the chart proves otherwise. For now, PFSA is a headline-driven trade, and this acquisition headline landed on the wrong side of the tape.
Conclusion
Profusa Inc. is giving traders a textbook case of how corporate headlines interact with fragile fundamentals. PFSA’s sharp 18% drop on the non-binding acquisition news shows the market is not willing to blindly reward big strategic swings when the balance sheet is this weak. Traders see the numbers: negative equity, limited cash, and steady operating losses. Layering an acquisition on top of that raises more questions than answers.
At the same time, PFSA remains a high-volatility trading vehicle. The recent run from sub-$1 levels to multi-dollar prints, plus wide intraday ranges, proves that momentum money likes this ticker. For day traders and swing traders, PFSA can be an opportunity — but only if risk is managed with discipline and no one confuses a trading setup with a long-term safety net. As Tim Bohen, lead trainer with StocksToTrade says, “If you’re still guessing at the end of your analysis, it’s probably not a trade worth taking.” In a name as volatile and speculative as PFSA, that kind of clarity is crucial before hitting the buy or sell button.
The key now is reaction, not just news. How PFSA trades around this 18% selloff, and what Profusa Inc. eventually discloses about deal terms and funding, will set up the next big move. Until then, this is a classic “plan the trade, trade the plan” scenario. As Tim Sykes likes to say, “Hype is temporary, but risk management is forever” — and PFSA is reminding traders exactly why that lesson matters.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.